Through the release of inflammasome activation, the cation channel TMEM176B has surfaced as a possible novel immunoregulatory target that might interfere with CD8+ T cell‐mediated tumor growth suppression.[30] Prior research mostly concentrated on TMEM176B's roles in TAMs,[31] while our studies further demonstrated the potential role of tumor‐derived TMEM176B in ICB resistance (Figure S3A–C, Supporting Information). Here, TMEM176B is linked to neoplasm.